NCT00983047 2015-08-27
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 2 Terminated
Biotech Pharmaceutical Co., Ltd.
Sir Mortimer B. Davis - Jewish General Hospital
YM BioSciences